Dr Antonio Pardinas

(e/fe)

PhD MSRB FHEA

2026

• Hadfield, O. et al. 2026. W125. Using physical and mental health polygenic risk scores to identify subtypes of schizophrenia and related diagnoses. European Neuropsychopharmacology 111 (S1) 113243. (10.1016/j.euroneuro.2026.113243)
• O'Connell, K. et al., 2026. W124. Dissecting shared and disorder-differentiating genetic architecture in schizophrenia and bipolar disorder [Abstract]. European Neuropsychopharmacology 111 (S1) 113242. (10.1016/j.euroneuro.2026.113242)
• Segura, P. et al., 2026. F101. Can we sample psychosis spectrum cases from population-based cohorts? Genetic and neuroanatomical evidence from the UK Biobank [Abstract]. European Neuropsychopharmacology 111 (Supple) 113496. (10.1016/j.euroneuro.2026.113496)
• Kraft, J. et al., 2026. T33. Investigating the shared genetic basis of treatment resistance across schizophrenia, major depression, and bipolar disorder [Abstract]. European Neuropsychopharmacology 111 (S1) 113290. (10.1016/j.euroneuro.2026.113290)
• Wong, C. et al., 2026. T118. Mitochondrial DNA variants affecting the risk for schizophrenia diagnosis [Abstract]. European Neuropsychopharmacology 111 113375. (10.1016/j.euroneuro.2026.113375)
• Caseras, X. et al. 2026. Common alleles associated with connectivity within and across the brain’s main functional networks. Nature Communications (10.1038/s41467-026-77476-2)
• Sadik, A. et al. 2026. Antidepressant prescribing trends for adults with and without autism in the United Kingdom from 1997 to 2023: A population-based cohort study using clinical practice research Datalink Aurum. Autism Research e70360. (10.1002/aur.70360)
• Yao, K. et al., 2026. Integrating genome-wide and epigenome-wide associations for antipsychotic induced extrapyramidal side effects. Psychopharmacology 243 , pp.1631-1642. (10.1007/s00213-025-06912-w)
• Gonçalves, V. et al., 2026. 273. Largest study of mitochondrial DNA variants increasing risk for schizophrenia [Abstract]. Biological Psychiatry 99 (10), pp.S216-S216. (10.1016/j.biopsych.2026.03.507)
• Smart, S. E. et al. 2026. Genetics to Improve Outcomes in Schizophrenia (GENios): A within-case molecular genetic study protocol. PLoS ONE 21 (2) e0340584. (10.1371/journal.pone.0340584)
• Kraft, J. et al., 2026. Identifying drug targets for schizophrenia through gene prioritization. Translational Psychiatry 16 102. (10.1038/s41398-026-03813-0)
• Murtough, S. et al., 2026. ACKR1 genetic testing should be offered before starting clozapine treatment. Nature Mental Health 4 , pp.30-41. (10.1038/s44220-025-00554-9)
• Lock, S. K. et al. 2026. Near, far, wherever you are: phenotype-related variation in pharmacogenomic effect sizes across the psychiatric drug literature. Frontiers in Pharmacology 16 1719761. (10.3389/fphar.2025.1719761)
• Chalk, J. et al. 2026. W128. Fine-mapping the disorder-differentiating genetics of schizophrenia and bipolar disorder using in-sample LD [Abstract]. European Neuropsychopharmacology 111 (Supple) 113246. (10.1016/j.euroneuro.2026.113246)
• Sadik, A. et al., 2026. Changes in the profile of adults diagnosed as autistic since 2010: population based studies in the United Kingdom and Sweden. BMJ Mental Health

2025

• Walters, J. , Willcocks, I. and Pardinas, A. 2025. Current Trends in Genetic Research [b. Genetic Research]. In: Albertson, D. N. et al., Research Methods in Mental Health: A Comprehensive Guide. Cambridge: Cambridge University Press. , pp.267-312. (10.1017/9781009028967.016)
• Smart, S. E. et al. 2025. The role of SLC39A8.p.( Ala391Thr ) in schizophrenia symptom severity and cognitive ability: cross‐sectional studies of schizophrenia and the general UK population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 198 (7), pp.135-146. (10.1002/ajmg.b.33037)
• Edwards, A. et al. 2025. Large language model–supported identification of intellectual disabilities in clinical free-text summaries: mixed methods study. JMIR AI 4 e72256. (10.2196/72256)
• Baune, B. T. et al., 2025. A stratified treatment algorithm in psychiatry: a program on stratified pharmacogenomics in severe mental illness (Psych-STRATA): concept, objectives and methodologies of a multidisciplinary project funded by Horizon Europe. European Archives of Psychiatry and Clinical Neuroscience 275 , pp.1453-1464. (10.1007/s00406-024-01944-3)
• Kappel, D. et al. 2025. Association between genetic liability to physical health conditions and comorbidities in individuals with severe mental illness: an analysis of two cross-sectional observational studies in the UK. The Lancet Psychiatry 12 (6), pp.447-456. (10.1016/S2215-0366(25)00123-3)
• Koch, E. et al., 2025. Recommendations for defining treatment outcomes in major psychiatric disorders using real-world data. The Lancet Psychiatry 12 (6), pp.457-468. (10.1016/S2215-0366(25)00061-6)
• Lock, S. K. et al. 2025. Antipsychotic and pharmacogenomic effects on cross-sectional symptom severity and cognitive ability in schizophrenia. EBioMedicine 116 105745. (10.1016/j.ebiom.2025.105745)
• O'Connell, K. S. et al., 2025. Genomics yields biological and phenotypic insights into bipolar disorder. Nature 639 , pp.968-975. (10.1038/s41586-024-08468-9)

2024

• Owen, D. et al. 2024. AI for analyzing mental health disorders among social media users: Quarter-century narrative review of progress and challenges. Journal of Medical Internet Research 26 e59225. (10.2196/59225)
• Woolway, G. E. et al., 2024. Assessing the validity of a self-reported clinical diagnosis of schizophrenia. Schizophrenia 10 (1) 99. (10.1038/s41537-024-00526-5)
• Koch, E. et al., 2024. How real-world data can facilitate the development of precision medicine treatment in psychiatry. Biological Psychiatry 96 (7), pp.543-551. (10.1016/j.biopsych.2024.01.001)
• Legge, S. E. et al. 2024. Genetic and phenotypic features of Schizophrenia in the UK Biobank. JAMA Psychiatry 81 , pp.681-690. (10.1001/jamapsychiatry.2024.0200)
• Sportelli, L. et al., 2024. Dopamine signaling enriched striatal gene set predicts striatal dopamine synthesis and physiological activity in vivo. Nature Communications 15 (1) 3342. (10.1038/s41467-024-47456-5)
• Caseras, X. et al. 2024. Common risk alleles for schizophrenia within the major histocompatibility complex predict white matter microstructure. Translational Psychiatry 14 194. (10.1038/s41398-024-02910-2)
• Kappel, D. et al. 2024. Rare variants in pharmacogenes influence clozapine metabolism in individuals with schizophrenia. European Neuropsychopharmacology 80 , pp.47-54. (10.1016/j.euroneuro.2023.12.007)

2023

• Guintivano, J. et al., 2023. Meta-analyses of genome-wide association studies for postpartum depression. The American Journal of Psychiatry 180 (12), pp.884-895. (10.1176/appi.ajp.20230053)
• Griffiths, K. et al., 2023. Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophrenia. Schizophrenia Research 260 , pp.152-159. (10.1016/j.schres.2023.08.020)
• Yuan, K. et al., 2023. Fine-mapping across diverse ancestries drives the discovery of putative causal variants underlying human complex traits and diseases. European Neuropsychopharmacology 75 (Supp 1), pp.S6-S7. (10.1016/j.euroneuro.2023.08.021)
• Lock, S. K. et al. 2023. Mediation and longitudinal analysis to interpret the association between clozapine pharmacokinetics, pharmacogenomics, and absolute neutrophil count. Schizophrenia 9 74. (10.1038/s41537-023-00404-6)
• Ollà, I. et al., 2023. Pathogenic mis-splicing of CPEB4 in schizophrenia. Biological Psychiatry 94 (4), pp.341-351. (10.1016/j.biopsych.2023.03.010)
• Chen, Z. et al., 2023. The contribution of Neanderthal introgression and natural selection to neurodegenerative diseases. Neurobiology of Disease 180 106082. (10.1016/j.nbd.2023.106082)
• Millgate, E. et al., 2023. Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study. Schizophrenia Research 255 , pp.173-181. (10.1016/j.schres.2023.03.020)
• Lynham, A. J. et al. 2023. DRAGON-Data: A platform and protocol for integrating genomic and phenotypic data across large psychiatric cohorts. BJPsych Open 9 (2) e32. (10.1192/bjo.2022.636)
• Pardinas, A. F. et al. 2023. Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data. The Lancet Psychiatry 10 (3), pp.209-219. (10.1016/S2215-0366(23)00002-0)
• Owen, D. et al. 2023. Enabling early health care intervention by detecting depression in users of web-based forums using Language models: longitudinal analysis and evaluation. JMIR AI 2 e41205. (10.2196/41205)
• Manca, R. , Pardinas, A. and Venneri, A. 2023. The neural signatures of psychoses in Alzheimer’s disease: a neuroimaging genetics approach. European Archives of Psychiatry and Clinical Neuroscience 273 , pp.253-267. (10.1007/s00406-022-01432-6)
• Pillinger, T. et al., 2023. Effect of polygenic risk for schizophrenia on cardiac structure and function: a UK Biobank observational study. The Lancet Psychiatry 10 (2), pp.98-107. (10.1016/S2215-0366(22)00403-5)
• Kappel, D. B. et al. 2023. Genomic stratification of clozapine prescription patterns using schizophrenia polygenic scores. Biological Psychiatry 93 , pp.149-156. (10.1016/j.biopsych.2022.07.014)

2022

• Pistis, G. et al., 2022. Gene set enrichment analysis of pathophysiological pathways highlights oxidative stress in psychosis. Molecular Psychiatry 27 , pp.5135-5143. (10.1038/s41380-022-01779-1)
• Smart, S. E. et al. 2022. Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium. Schizophrenia Research 250 , pp.1-9. (10.1016/j.schres.2022.09.009)
• D’Ambrosio, E. et al., 2022. A polygenic score indexing a DRD2 -related co-expression network is associated with striatal dopamine function. Scientific Reports 12 (1) 12610. (10.1038/s41598-022-16442-6)
• Trubetskoy, V. et al., 2022. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. Nature 604 , pp.502-508. (10.1038/s41586-022-04434-5)
• Okhuijsen-Pfeifer, C. et al., 2022. Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders. Translational Psychiatry 12 145. (10.1038/s41398-022-01884-3)
• Alonso-Llamazares, C. , Lopez, B. and Pardinas, A. 2022. Sex differences in the distribution of entheseal changes Meta-analysis of published evidence and its use in Bayesian paleopathological modelling. American Journal of Physical Anthropology 177 (2), pp.249-265. (10.1002/ajpa.24425)
• Sanders, B. et al. 2022. Transcriptional programs regulating neuronal differentiation are disrupted in DLG2 knockout human embryonic stem cells and enriched for schizophrenia and related disorders risk variants. Nature Communications 13 (1) 27. (10.1038/s41467-021-27601-0)
• Pardinas, A. et al. 2022. Interaction testing and polygenic risk scoring to estimate the contribution of common genetic variants to treatment resistance in schizophrenia. JAMA Psychiatry 79 (3), pp.260-269. (10.1001/jamapsychiatry.2021.3799)

2021

• Di Florio, A. et al. 2021. Post-partum psychosis and its association with bipolar disorder in the UK: a case-control study using polygenic risk scores. The Lancet Psychiatry 8 (12), pp.1045-1052. (10.1016/S2215-0366(21)00253-4)
• Pardinas, A. F. , Owen, M. J. and Walters, J. T. 2021. Pharmacogenomics: A road ahead for precision medicine in psychiatry. Neuron 109 (24), pp.3914-3929. (10.1016/j.neuron.2021.09.011)
• Clifton, N. E. et al. 2021. Developmental profile of psychiatric risk associated with voltage-gated cation channel activity. Biological Psychiatry 90 (6)(10.1016/j.biopsych.2021.03.009)
• Martin, J. et al. 2021. Examining sex differences in neurodevelopmental and psychiatric genetic risk in anxiety and depression. PLoS ONE 16 (9) e0248254. (10.1371/journal.pone.0248254)
• Cleynen, I. et al., 2021. Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. Molecular Psychiatry , pp.4496-4510. (10.1038/s41380-020-0654-3)
• Legge, S. et al. 2021. Associations between schizophrenia polygenic liability, symptom dimensions, and cognitive ability in schizophrenia. JAMA Psychiatry 78 (10), pp.1143-1151. (10.1001/jamapsychiatry.2021.1961)
• Alonso-Llamazares, C. et al., 2021. Assessing individual and population variability in degenerative joint disease prevalence using generalized linear mixed models. American Journal of Physical Anthropology 175 (3), pp.611-625. (10.1002/ajpa.24195)
• Clifton, N. E. et al. 2021. Genetic association of FMRP targets with psychiatric disorders. Molecular Psychiatry 26 , pp.2977-2990. (10.1038/s41380-020-00912-2)
• Hubbard, L. et al. 2021. Rare copy number variations are associated with poorer cognition in schizophrenia. Biological Psychiatry 90 (1), pp.28-34. (10.1016/j.biopsych.2020.11.025)
• Byrne, E. et al., 2021. Conditional GWAS analysis to identify disorder-specific SNPs for psychiatric disorders. Molecular Psychiatry 26 , pp.2070-2081. (10.1038/s41380-020-0705-9)
• Mullins, N. et al., 2021. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics 53 , pp.817-829. (10.1038/s41588-021-00857-4)
• Willcocks, I. et al. 2021. Clozapine metabolism is associated with absolute neutrophil count in individuals with treatment-resistant schizophrenia. Frontiers in Pharmacology 12 658734. (10.3389/fphar.2021.658734)
• Konte, B. et al., 2021. HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry. Translational Psychiatry 11 214. (10.1038/s41398-021-01322-w)

2020

• Santiago, E. et al., 2020. Recent demographic history inferred by high-resolution analysis of linkage disequilibrium. Molecular Biology and Evolution 37 (12), pp.3642-3653. (10.1093/molbev/msaa169)
• Kendall, K. M. et al. 2020. Impact of schizophrenia genetic liability on the association between schizophrenia and physical illness: a data linkage study. BJPsych Open 6 (6) e139. (10.1192/bjo.2020.42)
• Legge, S. E. et al. 2020. The Duffy-null genotype and risk of infection. Human Molecular Genetics 29 (20), pp.3341-3349. (10.1093/hmg/ddaa208)
• Grama, S. et al. 2020. Polygenic risk for schizophrenia and subcortical brain anatomy in the UK Biobank cohort. Translational Psychiatry 10 309. (10.1038/s41398-020-00940-0)
• Legge, S. et al. 2020. Clinical indicators of treatment-resistant psychosis. British Journal of Psychiatry 216 (5), pp.259-266. (10.1192/bjp.2019.120)
• Richards, A. et al. 2020. The relationship between polygenic risk scores and cognition in schizophrenia. Schizophrenia Bulletin 46 (2), pp.-. (10.1093/schbul/sbz061)
• Dennison, C. A. et al. 2020. Genome-wide association studies in schizophrenia: Recent advances, challenges and future perspective. Schizophrenia Research 217 , pp.4-12. (10.1016/j.schres.2019.10.048)
• Rees, E. et al. 2020. De novo mutations identified by exome sequencing implicate rare missense variants in SLC6A1 in schizophrenia. Nature Neuroscience 23 (2), pp.179-184. (10.1038/s41593-019-0565-2)
• Hall, L. S. et al. 2020. A transcriptome-wide association study implicates specific pre- and post-synaptic abnormalities in schizophrenia. Human Molecular Genetics 29 (1), pp.159-167. (10.1093/hmg/ddz253)

2019

• Legge, S. E. et al. 2019. Association of genetic liability to psychotic experiences with neuropsychotic disorders and traits. JAMA Psychiatry 76 (12), pp.1256-1265. (10.1001/jamapsychiatry.2019.2508)
• Chapman, R. M. et al., 2019. Convergent evidence that ZNF804A is a regulator of pre-messenger RNA processing and gene expression. Schizophrenia Bulletin 45 (6), pp.1267-1278. (10.1093/schbul/sby183)
• D'Ambrosio, E. et al., 2019. The effect of a genetic variant at the schizophrenia associated AS3MT/BORCS7 locus on striatal dopamine function: A PET imaging study. Psychiatry Research: Neuroimaging 291 , pp.34-41. (10.1016/j.pscychresns.2019.07.005)
• Pain, O. et al. 2019. Novel insight into the etiology of autism spectrum disorder gained by integrating expression data with genome-wide association statistics. Biological Psychiatry 86 (4), pp.265-273. (10.1016/j.biopsych.2019.04.034)
• Escott-Price, V. et al. 2019. The relationship between common variant schizophrenia liability and number of offspring in the UK Biobank. American Journal of Psychiatry 176 (8), pp.661-666. (10.1176/appi.ajp.2018.18020140)
• Pardinas, A. F. et al. 2019. Pharmacogenomic variants and drug interactions identified through the genetic analysis of clozapine metabolism. American Journal of Psychiatry 176 (6), pp.477-486. (10.1176/appi.ajp.2019.18050589)
• Pettersson, E. et al., 2019. Genetic influences on eight psychiatric disorders based on family data of 4 408 646 full and half-siblings, and genetic data of 333 748 cases and controls. Psychological Medicine 49 (7), pp.1166-1173. (10.1017/S0033291718002039)
• Huckins, L. M. et al., 2019. Gene expression imputation across multiple brain regions provides insights into schizophrenia risk. Nature Genetics 51 , pp.659-674. (10.1038/s41588-019-0364-4)
• Rees, E. et al. 2019. Targeted sequencing of 10,198 samples confirms abnormalities in neuronal activity and implicates voltage-gated sodium channels in schizophrenia pathogenesis. Biological Psychiatry 85 (7), pp.554-562. (10.1016/j.biopsych.2018.08.022)
• Legge, S. E. et al. 2019. A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia. Molecular Psychiatry 24 , pp.328-337. (10.1038/s41380-018-0335-7)

2018

• Li, M. et al., 2018. Integrative functional genomic analysis of human brain development and neuropsychiatric risks. Science 362 (6420) eaat7615. (10.1126/science.aat7615)
• O'Brien, H. E. et al. 2018. Expression quantitative trait loci in the developing human brain and their enrichment in neuropsychiatric disorders. Genome Biology 19 194. (10.1186/s13059-018-1567-1)
• Dahoun, T. et al., 2018. The effect of the DISC1 Ser704Cys polymorphism on striatal dopamine synthesis capacity: an [18F]-DOPA PET study. Human Molecular Genetics 27 (20), pp.3498-3506. (10.1093/hmg/ddy242)
• Alonso-Llamazares, C. et al., 2018. Medical diagnostic methods applied to a medieval female with vitamin D deficiency from the North of Spain. International Journal of Paleopathology 22 , pp.109-120. (10.1016/j.ijpp.2018.07.007)
• Skene, N. G. et al., 2018. Genetic identification of brain cell types underlying schizophrenia. Nature Genetics 50 , pp.825-833. (10.1038/s41588-018-0129-5)
• Pardinas, A. F. et al. 2018. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nature Genetics 50 , pp.381-389. (10.1038/s41588-018-0059-2)

2017

• Gomes, C. et al., 2017. Phenotyping the ancient world: the physical appearance and ancestry of very degraded samples from a chalcolithic human remains. Forensic Science International: Genetics Supplement Series 6 , pp.e484-e486. (10.1016/j.fsigss.2017.09.188)
• Legge, S. E. et al. 2017. Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Molecular Psychiatry 22 , pp.1502-1508. (10.1038/mp.2016.97)
• Hensman Moss, D. J. et al., 2017. Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology 16 (9), pp.701-711. (10.1016/S1474-4422(17)30161-8)
• Lopez, B. et al., 2017. Treponemal disease in the Old World? Integrated paleopathological assessment of a 9th-11th century skeleton from North-Central Spain. Anthropological Science 125 (2), pp.101-114. (10.1537/ase.170515)
• Allardyce, J. et al. 2017. Psychosis and the level of mood incongruence in bipolar disorder are related to genetic liability for schizophrenia. bioRxiv

2016

• Huelga-Suarez, G. et al., 2016. The quest for the Soldier's Rest: Combining anthropological and archaeochemical approaches to study social and occupational diversity in the Medieval graveyard of San Andres de Arroyo (Palencia, Spain). Anthropological Science 124 (3) 161005. (10.1537/ase.161005)
• Rees, E. et al. 2016. Analysis of intellectual disability copy number variants for association with schizophrenia. JAMA Psychiatry 73 (9), pp.963-969. (10.1001/jamapsychiatry.2016.1831)
• Pardinas, A. et al. 2016. Common schizophrenia alleles are enriched in mutation-intolerant genes and maintained by background selection. bioRxiv (10.1101/068593)
• Aas, M. et al., 2016. Summaries of plenary, symposia, and oral sessions at the XXII World Congress of Psychiatric Genetics, Copenhagen, Denmark, 12-16 October 2014 [Conference Material]. Psychiatric Genetics 26 (1), pp.1-47. (10.1097/YPG.0000000000000112)